Spotlight Session - Vaccines

(A49) Carditis risk following covid-19 vaccination with mRNA (BNT162b2) or inactivated (CoronaVac): a self-controlled cases series and a case-control study

(A50) Characterization of U.S. Adults Aged 18–64 Years Vaccinated Against Mpox within the Food and Drug Administration Biologics Effectiveness and Safety (BEST) Initiative

(A51) Evaluation of the risk of potential adverse events following bivalent COVID-19 vaccines in Veteran patients

(A52) Post-marketing surveillance of human papillomavirus (HPV)-related high-grade cervical disease in a cohort of Chinese women who received the 9-valent HPV vaccine

(A53) Safety monitoring of COVID-19 vaccines in multiple European countries: initial results from the COVID-19 Vaccine Monitor (CVM)

(A54) The effect of sex on the incidence, latency, duration and burden of adverse events following influenza vaccination

(A55) The importance of contextualising overall measures of COVID-19 vaccine effectiveness: the COVIDRIVE-AstraZeneca experience

(A56) Vaccine patterns among older adults diagnosed with Guillain-Barré Syndrome and matched counterparts with Medicare insurance, 2006-2019